January 2, 2024

Mark Ragosa Senior Vice President and Chief Financial Officer Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 Church Street Hamilton HM11, Bermuda

Re: Kiniksa

Pharmaceuticals, Ltd.

Form 10-K for the

Fiscal Year Ended December 31, 2022

Filed March 2, 2023 File No. 001-38492

Dear Mark Ragosa:

 $$\operatorname{\textsc{We}}$ have completed our review of your filing. We remind you that the company and its

management are responsible for the accuracy and adequacy of their disclosures, notwithstanding

any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc: Maddy Zeylikman